跳至内容
The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics 線上預覽
關閉線上預覽
正在查...

The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics

作者: J Geigert
出版商: New York, NY : Springer, ©2013.
版本/格式:   電子書 : 文獻 : 英語 : 2nd ed所有版本和格式的總覽
資料庫:WorldCat
提要:
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in  再讀一些...
評定級別:

(尚未評分) 0 附有評論 - 成爲第一個。

主題
更多類似這樣的

 

在線上查詢

與資料的連結

在圖書館查詢

&AllPage.SpinnerRetrieving; 正在查詢有此資料的圖書館...

詳細書目

類型/形式: Electronic books
資料類型: 文獻, 網際網路資源
文件類型: 網路資源, 電腦資料
所有的作者/貢獻者: J Geigert
ISBN: 9781461469162 1461469163
OCLC系統控制編碼: 843402928
描述: 1 online resource.
内容: Complexity of biologic CMC regulation --
Biologics are not chemical drugs --
An effective CMC strategy is possible --
Challenge of adventitious agent control --
Source materials for biologics --
Manufacture of the biologic API --
The biologic final product process --
Complex process-related impurities --
Molecular structural analysis --
Functional activity (Potency) --
Setting specifications and expiry dates --
Demonstrating product comparability --
CMC-focused regulatory meetings.
責任: John Geigert.
更多資訊:

摘要:

In its new edition, this book reviews the challenges facing quality assurance and control (QA/QC) in today's biopharmaceutical environment, putting into perspective the need for a graded approach to  再讀一些...

評論

讀者提供的評論
正在擷取GoodReads評論...
正在擷取DOGObooks的評論

標籤

成爲第一個
確認申請

你可能已經申請過這份資料。若還是想申請,請選確認。

連結資料


<http://www.worldcat.org/oclc/843402928>
library:oclcnum"843402928"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/843402928>
rdf:typeschema:Book
schema:about
schema:about
<http://id.loc.gov/authorities/subjects/sh00005579>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology industry--Law and legislation."
schema:about
<http://id.worldcat.org/fast/1060114>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology industry--Law and legislation"
schema:about
<http://id.worldcat.org/fast/1060109>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology--Quality control"
schema:about
schema:about
schema:about
schema:about
schema:about
<http://id.loc.gov/authorities/subjects/sh90004049>
rdf:typeschema:Intangible
schema:name"Pharmaceutical biotechnology--Quality control."
schema:name"Pharmaceutical biotechnology."
schema:about
schema:bookEdition"2nd ed."
schema:bookFormatschema:EBook
schema:copyrightYear"2013"
schema:creator
schema:datePublished"2013"
schema:description"An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals). About The Author John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an expert member of the USP Biotechnology Committee. Dr. Geigert has written extensively for the Regulatory Affairs Professional Society (RAPS) Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series) and Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series))."
schema:exampleOfWork<http://worldcat.org/entity/work/id/673009>
schema:genre"Electronic books."
schema:inLanguage"en"
schema:name"The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics"
schema:publisher
schema:url<http://dx.doi.org/10.1007/978-1-4614-6916-2>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=580248>
schema:url
schema:url<http://site.ebrary.com/id/10699675>
schema:workExample

Content-negotiable representations

關閉視窗

請登入WorldCat 

没有帳號嗎?你可很容易的 建立免費的帳號.